| dc.contributor.author |
Kasiotis, KM |
en |
| dc.contributor.author |
Mendorou, C |
en |
| dc.contributor.author |
Haroutounian, SA |
en |
| dc.contributor.author |
Alexis, MN |
en |
| dc.date.accessioned |
2014-06-06T06:47:18Z |
|
| dc.date.available |
2014-06-06T06:47:18Z |
|
| dc.date.issued |
2006 |
en |
| dc.identifier.issn |
0039128X |
en |
| dc.identifier.uri |
http://dx.doi.org/10.1016/j.steroids.2005.10.004 |
en |
| dc.identifier.uri |
http://62.217.125.90/xmlui/handle/123456789/3514 |
|
| dc.subject |
17α-Alkynylazido estradiol derivatives |
en |
| dc.subject |
Estrogenic activity |
en |
| dc.subject.other |
17alpha (5 azido pent 1 ynyl) 3,17beta estradiol |
en |
| dc.subject.other |
17alpha (azidopentyn 2 yl) 3,17beta estradiol |
en |
| dc.subject.other |
17alpha (azidopropargyl) 3,17beta estradiol |
en |
| dc.subject.other |
17alpha 17 (3 azido prop 1 ynyl) 13 methyl 7,8,9,11,12,13,14,15,16,17 decahydro 6h cyclopenta[a]phenanthren 3 ol |
en |
| dc.subject.other |
17alpha estradiol |
en |
| dc.subject.other |
alkaline phosphatase |
en |
| dc.subject.other |
antiestrogen |
en |
| dc.subject.other |
azide |
en |
| dc.subject.other |
estradiol derivative |
en |
| dc.subject.other |
estrogen receptor |
en |
| dc.subject.other |
estrogen receptor alpha |
en |
| dc.subject.other |
estrogen receptor beta |
en |
| dc.subject.other |
hormone receptor stimulating agent |
en |
| dc.subject.other |
luciferase |
en |
| dc.subject.other |
unclassified drug |
en |
| dc.subject.other |
drug derivative |
en |
| dc.subject.other |
estradiol |
en |
| dc.subject.other |
article |
en |
| dc.subject.other |
binding affinity |
en |
| dc.subject.other |
breast cancer |
en |
| dc.subject.other |
cancer cell |
en |
| dc.subject.other |
cell clone |
en |
| dc.subject.other |
cell line |
en |
| dc.subject.other |
cell proliferation |
en |
| dc.subject.other |
concentration response |
en |
| dc.subject.other |
controlled study |
en |
| dc.subject.other |
drug activity |
en |
| dc.subject.other |
drug efficacy |
en |
| dc.subject.other |
drug potency |
en |
| dc.subject.other |
drug receptor binding |
en |
| dc.subject.other |
drug synthesis |
en |
| dc.subject.other |
endometrium cancer |
en |
| dc.subject.other |
enzyme induction |
en |
| dc.subject.other |
estrogen activity |
en |
| dc.subject.other |
gene expression |
en |
| dc.subject.other |
genetic transfection |
en |
| dc.subject.other |
hormone response |
en |
| dc.subject.other |
human |
en |
| dc.subject.other |
human cell |
en |
| dc.subject.other |
photoaffinity labeling |
en |
| dc.subject.other |
breast tumor |
en |
| dc.subject.other |
cell culture |
en |
| dc.subject.other |
drug potentiation |
en |
| dc.subject.other |
endometrium tumor |
en |
| dc.subject.other |
evaluation |
en |
| dc.subject.other |
female |
en |
| dc.subject.other |
metabolism |
en |
| dc.subject.other |
pathology |
en |
| dc.subject.other |
protein binding |
en |
| dc.subject.other |
structure activity relation |
en |
| dc.subject.other |
synthesis |
en |
| dc.subject.other |
Mink cell focus-forming virus |
en |
| dc.subject.other |
Alkaline Phosphatase |
en |
| dc.subject.other |
Breast Neoplasms |
en |
| dc.subject.other |
Endometrial Neoplasms |
en |
| dc.subject.other |
Estradiol |
en |
| dc.subject.other |
Estrogen Receptor alpha |
en |
| dc.subject.other |
Estrogen Receptor beta |
en |
| dc.subject.other |
Female |
en |
| dc.subject.other |
Humans |
en |
| dc.subject.other |
Luciferases |
en |
| dc.subject.other |
Protein Binding |
en |
| dc.subject.other |
Structure-Activity Relationship |
en |
| dc.subject.other |
Tumor Cells, Cultured |
en |
| dc.title |
High affinity 17α-substituted estradiol derivatives: Synthesis and evaluation of estrogen receptor agonist activity |
en |
| heal.type |
journalArticle |
en |
| heal.identifier.primary |
10.1016/j.steroids.2005.10.004 |
en |
| heal.publicationDate |
2006 |
en |
| heal.abstract |
We synthesized four derivatives of 17β-estradiol (E2) with an azide substitution on a 17α-side chain of varying length, namely 17α-(azidopropargyl)-3,17β-estradiol (5), its 17β-azido derivative (diazide 7), 17α-(5-azido-pent-1-ynyl)-3,17β-estradiol (6) and 17α-(azidopentyn-2-yl)-3,17β-estradiol (10). While most of the derivatives had low (7) or marginal (6 and 10) relative binding affinity (RBA) for both types of estrogen receptor (ERα and ERβ), the RBAα and RBAβ of 5 were practically identical to those of E2. The estrogenic activity of the derivatives was assessed using estrogen-responsive breast (MCF-7) and endometrial cancer (Ishikawa) cells. While 5 was a potent and effective inducer of alkaline phosphatase in Ishikawa cells and 7 was less potent but as effective as 5, 6 was marginally active and 10 was totally inactive in this respect. In the presence of 0.1 nM E2, however, 6 exhibited some ER antagonist activity at the highest concentration tested (1 μM). Similar results were obtained as regards the potency and efficacy of stimulation of MCF-7 cell proliferation and induction of luciferase gene expression in MCF-7:D5L cells, a clone stably transfected with an estrogen-responsive form of the gene. These data suggest that, while 5, 6, 7 and 10 interact with either type of ER in isolation, only 5 and 7 exhibit substantial ER agonist activity in the different estrogen-target cells examined, which could provide for photoaffinity labelling of the receptor in the cell as well as in isolation. © 2005 Elsevier Inc. All rights reserved. |
en |
| heal.journalName |
Steroids |
en |
| dc.identifier.issue |
3 |
en |
| dc.identifier.volume |
71 |
en |
| dc.identifier.doi |
10.1016/j.steroids.2005.10.004 |
en |
| dc.identifier.spage |
249 |
en |
| dc.identifier.epage |
255 |
en |